Clinical Trial Update: First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER) [Phase 1, Phase 2]

View source ↗

Summary

First-in-human study of Visugromab (CTL-002), a GDF-15 neutralizing antibody, in adults with advanced solid tumors (Phase 1/2). The trial status is active but n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Visugromab (Visugromab)

Snippet

Sponsor: CatalYm GmbH | Conditions: Solid Tumor, Adult | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING